Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12634828 | 0.97 | PDE10A (0.38) | PDE10APDE4B | |
| SCHEMBL12634855 | 0.93 | PDE10A (0.44) | PDE10APDE4B | |
| SCHEMBL12634805 | 0.70 | PDE10A (0.40) | PDE10A | |
| SCHEMBL2271668 | 0.69 | PDE10A (0.42) | PDE10A | |
| SCHEMBL12635005 | 0.68 | PDE4B (0.36) | PDE10APDE4B | |
| SCHEMBL30095835 | 0.67 | PDE10A (0.48) | PDE10APDE4B | |
| SCHEMBL30095928 | 0.67 | PDE10A (0.48) | PDE10APDE4B | |
| SCHEMBL12634760 | 0.67 | PDE10A (0.40) | PDE10A | |
| SCHEMBL15947899 | 0.66 | PDE10A (0.36) | PDE10A | |
| SCHEMBL4419024 | 0.65 | PDE10A (0.83) | PDE10APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7947690-B2 | Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example | ASTELLAS PHARMA INC. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-7947690-B2 | Insulin secretagogue and hypoglycemic agent; pyrimidine derivatives condensed with a non-aromatic ring selected from dihydrothiophene, dihydrofuran, cycloalkane moiety; 1-[2-(4-chloro-2,5-difluorophenyl)-6,6-dioxido-5,7-dihydrothieno[3,4-d]pyrimidin-4-yl]-4-(3-hydroxypropyl)piperidin-4-ol for example | ASTELLAS PHARMA INC. (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | ASTELLAS PHARMA INC. (JP) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070896-A1 | Pyrimidine Derivative Condensed with a Non-Aromatic Ring | GPR119, IRS1, NONO | PDE10A 3700/4885PDE4B 3723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.